Global Colorectal Cancer Molecular Diagnostics Market Overview 2033 : Forecasted Market Size And Growth Rate | Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation

"The colorectal cancer molecular diagnostics market size has grown strongly in recent years. It will grow from $2.35 billion in 2023 to $2.56 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increasing incidence of colorectal cancer, growing awareness and screening initiatives, rising emphasis on personalized medicine, government initiatives for cancer control..

The colorectal cancer molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.48 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to aging population and increased risk factors, integration of genomic data into clinical practice, rise in precision medicine approaches, global efforts in cancer research and collaboration.. Major trends in the forecast period include increasing emphasis on early detection biomarkers, integration of artificial intelligence (ai) in data analysis, rise of circulating tumor dna (ctdna) analysis, expansion of companion diagnostics for targeted therapies, focus on immunotherapy biomarkers..

Market Overview -
Colorectal cancer, also known as colon cancer or rectal cancer, is a malignant tumor that develops in the colon (the large intestine) or (the final portion of the digestive tract just before the anus). It is a type of cancer that arises from the inner lining of these parts of the gastrointestinal system. Colorectal cancer molecular diagnostics uses advanced techniques to identify specific genetic mutations, alterations, and biomarkers that play a role in the development, progression, and treatment response of colorectal cancer.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp

Rising Incidence Of Inflammatory Bowel Diseases (IBD) Sparks Growth In Colorectal Cancer Molecular Diagnostic Market
The increasing incidence of inflammatory bowel diseases (IBD) is expected to propel the growth of the colorectal cancer molecular diagnostic market going forward. Inflammatory bowel diseases (IBD) are chronic gastrointestinal disorders characterized by digestive tract inflammation, primarily affecting the colon with symptoms like abdominal pain, diarrhea, and weight loss, managed through medications, lifestyle changes, and sometimes surgery. The increasing incidence of inflammatory bowel diseases fuels the demand for accurate, efficient, and advanced diagnostic solutions that play an essential role, as the determination of systemic therapy for colorectal cancer (CRC) predominantly relies on the result obtained from molecular assessment of the tumor. For instance, in May 2021, according to BioMed Central Ltd., a UK-based scientific open-access publisher, the number of inflammatory bowel disease (IBD) cases is projected to increase 2.5 times compared to 2020, with approximately 69,000 cases in Iran, 220,000 cases in the Middle East, 2.2 million cases in India, and a significant 4.5 million cases in East Asia during 2020-2035. Therefore, increasing incidences of inflammatory bowel diseases (IBD) will drive the growth of the colorectal cancer molecular diagnostic market.

Competitive Landscape -
Major companies operating in the colorectal cancer molecular diagnostics market report are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

Innovative Molecular Diagnostics And Personalized Medicine Solutions In Colorectal Cancer Guardant Health's Shield Blood Test
Major companies operating in the colorectal cancer molecular diagnostic market focus on developing innovative molecular diagnostics and personalized medicine solutions, such as the shield blood test approach to identify colorectal cancer at an earlier, more treatable stage. Shield Blood Test, an initial blood test designed to identify early-stage colorectal cancer (CRC). For instance, in May 2022, Guardant Health, a US-based biotechnology company offering oncology molecular diagnostic products, launched its Shield Blood Test. The susceptible shield test provides a convenient screening option that involves a simple blood draw to address challenges related to patients' willingness to get screened. The test showed a sensitivity of 91% for detecting colorectal cancer and 20% for detecting advanced adenomas, and the specificity was measured at 92%. The Shield test identifies early colorectal cancer signals in the blood by utilizing data from diverse cohorts of over 2,000 subjects with colorectal cancer, 357 with advanced adenoma, and 3,757 normal subjects.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Key Segments -
The colorectal cancer molecular diagnostics market covered in this report is segmented -

1) By Type: Instruments, Reagents And Kits, Services
2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.